Astellas’ Padcev, Pfizer’s JAK Inhibitor, AZ’s Lupus Drug Clear PAFSC Panel

September 7, 2021
A key health ministry advisory body gave the blessing for a batch of new medicines for regulatory approval on September 6, including Astellas Pharma’s antibody-drug conjugate (ADC) Padcev (enfortumab vedotin). Their official greenlight is expected as early as this month...read more